0.829
IF
20
MNiSW
166.26
ICV
RESEARCH PAPER
 
CC BY-NC-ND 3.0
 
 

Differences in achieving treatment goals with statin use in various regions of Poland – 3ST-POL study results

Daniel Śliż 1, 2  ,  
 
1
3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland
2
Public Health School, Centre of Postgraduate Medical Education, Poland
3
1st Department of Cardiology, Medical University of Warsaw, Poland
4
Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Poland
5
Department of Family Medicine. Medical University of Gdansk, Poland
Ann Agric Environ Med 2016;23(1):116–119
KEYWORDS:
ABSTRACT:
Introduction and objective:
Dyslipidemia is the most common factor leading to ischemic heart disease, which is one of the leading causes of death. The use of statins is the most important preventative measure of ischemic heart disease; however, their efficacy in patients in Poland is still too low. The purpose of this study was to evaluate regional differences in achieving treatment goals in total cholesterol (TC) and LDL cholesterol levels in patients treated with statins on an outpatient basis.

Material and Methods:
A survey was used to evaluate efficacy of treatment, completed by 49,950 patients in Poland treated with statins in 2008. The territory of Poland was divided into 4 research regions: the Northeast (NE), Northwest (NW), Southeast (SE), and Southwest (SW) regions.

Results:
The largest group of patients resided in the SW region, the smallest in the SE region. Participants of the study suffered from hypercholesterolemia, on average, for at least a year before completing the study survey. Effective treatment leading to achievement of target TC was observed in less than 10% of the patients. Rate of achievement of target cholesterol levels was highest in the NE region, lowest in the NW region. Cardiologists were more successful in achieving therapeutic goals than GPs. Similar correlations between regions and doctors’ specializations were observed for LDL values.

Conclusions:
Significant differences in the efficacy of treatment with statins were observed among the study group and were evaluated based on achievement of target TC and LDL cholesterol levels. Better results achieved in the NE region may be because the region includes the Masovian province, which is the most economically developed region in Poland.

CORRESPONDING AUTHOR:
Daniel Śliż   
3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland
 
REFERENCES:
1. Dane statystyczne dotyczące przyczyn zgonu. http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Causes_of_death_statistics/pl (access: 10.02.2013).
2. Piwonska A, Piotrowski W, Broda G. Ten-year risk of fatal cardiovascular disease in the Polish population and medical care. Results of the WOBASZ study. Kardiol Pol. 2010; 68: 672–677.
3. Jaki jest stan zdrowia Polaków według NATPOL 2011? http://www.termedia.pl/Jaki-jest-stan-zdrowia-Polakow-wedlug-NATPOL-2011-,4624.html (access: 10.02.2013).
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol – lowering treatment: prospective meta – analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78. doi:10.1016/S0140 – 6736(05)67394 – 1 PMID:16214597.
5. Heart Protection Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22.
6. Gotto AM Jr, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies Am J Cardiol. 2012; 110(1 Suppl): 15A-26A.
7. Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D, Graham I. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prev Cardiol. 2012 Apr 18.
8. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295(2): 180–189.
9. Sliz D, Mamcarz A, Filipiak KJ, Siebert J, Naruszewicz M. 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol Arch Med Wewn. 2010; 120(9): 328–33.
10. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929–940.
11. Filipiak K, Pietrasik A, Starczewska M, et al. Polish country-wide, multicentre system of monitoring the standard of primary cardiological care in GP surgeries (POLCAD – SPOK): methods used during realization of the programme. Kardiol Pol. 2006; 64(8): S167-S171.
12. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies. Eur J Cardiovasc Prev Rehabil. 2007; 14(Suppl 2): S1–S113.
13. Sliz D, Filipiak KJ, Naruszewicz M, Siebert J, Mamcarz A. Standard of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiol Pol. 2013; 71(3): 253–259.
14. Fifth Joint Task Force of the European Society of Cardiology. European Guidelines on cardiovascular disease prevention in clinical practice: the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012; 19(4): 586–667.
eISSN:1898-2263
ISSN:1232-1966